Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport.

Shen L, Peng HC, Nees SN, Zhao SP, Xu DY.

FEBS Lett. 2013 May 2;587(9):1271-4. doi: 10.1016/j.febslet.2013.02.027.

2.

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL.

Atherosclerosis. 2012 Feb;220(2):381-6. doi: 10.1016/j.atherosclerosis.2011.11.026.

PMID:
22176652
3.

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, Wasserman SM, Princen HM, Jackson S.

J Lipid Res. 2014 Nov;55(11):2370-9. doi: 10.1194/jlr.M053207.

4.

Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.

Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, Prat A.

Neoplasia. 2012 Dec;14(12):1122-31.

5.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Review.

6.

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.

Lipari MT, Li W, Moran P, Kong-Beltran M, Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic A, Arnott D, Wang J, Peterson AS, Kirchhofer D.

J Biol Chem. 2012 Dec 21;287(52):43482-91. doi: 10.1074/jbc.M112.380618.

7.

Local effects of human PCSK9 on the atherosclerotic lesion.

Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S.

J Pathol. 2016 Jan;238(1):52-62. doi: 10.1002/path.4630.

PMID:
26333678
8.

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G.

Biochem Biophys Res Commun. 2008 Jun 13;370(4):634-40. doi: 10.1016/j.bbrc.2008.04.004.

PMID:
18406350
9.

Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

Duan Y, Chen Y, Hu W, Li X, Yang X, Zhou X, Yin Z, Kong D, Yao Z, Hajjar DP, Liu L, Liu Q, Han J.

J Biol Chem. 2012 Jul 6;287(28):23667-77. doi: 10.1074/jbc.M112.350181.

10.
11.

[Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].

Avci A, Demir K, Altunkeser BB.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 2:56-67. Review. Turkish.

12.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.

Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354.

PMID:
18666258
13.

Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.

Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, Seidah NG, Prat A.

Circulation. 2012 Feb 21;125(7):894-901. doi: 10.1161/CIRCULATIONAHA.111.057406.

14.

Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.

Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin MC, Roubtsova A, Hamelin J, Marcinkiewicz J, Chamberland A, Guillemot J, Mayer G, Sisodia SS, Jacob Y, Prat A, Seidah NG.

J Biol Chem. 2015 Jul 24;290(30):18609-20. doi: 10.1074/jbc.M115.647180.

16.
17.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.

PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145.

18.

PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.

Demers A, Samami S, Lauzier B, Des Rosiers C, Ngo Sock ET, Ong H, Mayer G.

Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2517-25. doi: 10.1161/ATVBAHA.115.306032.

19.

PCSK9 and its modulation.

Cui CJ, Li S, Li JJ.

Clin Chim Acta. 2015 Feb 2;440:79-86. doi: 10.1016/j.cca.2014.10.044. Review.

PMID:
25444750
20.

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A.

Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):785-91. doi: 10.1161/ATVBAHA.110.220988.

Items per page

Supplemental Content

Support Center